Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer
Summary Background Nanoparticle albumin-bound paclitaxel ( nab -paclitaxel) is a Cremophor EL–free formulation of paclitaxel newly designed to avoid solvent-related toxicities. We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab -paclitaxel (100 mg/...
Gespeichert in:
Veröffentlicht in: | Investigational new drugs 2012-06, Vol.30 (3), p.1132-1137 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Summary
Background
Nanoparticle albumin-bound paclitaxel (
nab
-paclitaxel) is a Cremophor EL–free formulation of paclitaxel newly designed to avoid solvent-related toxicities. We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly
nab
-paclitaxel (100 mg/m
2
) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced non–small cell lung cancer (NSCLC).
Methods Nab
-paclitaxel (100 mg/m
2
) was administered without steroid or antihistamine premedication as a 30-min intravenous infusion once a week in combination with carboplatin at an AUC of 6 on day 1 of repeated 21-day cycles. The pharmacokinetics of both drugs were analyzed, and both adverse events and treatment response were monitored.
Results
Eighteen patients were enrolled in the study. The most frequent treatment-related toxicities of grade 3 or 4 were neutropenia (67%), leukopenia (50%), and anemia (22%). No severe hypersensitivity reactions were observed despite the lack of premedication, and no unexpected or new toxicities were detected. Pharmacokinetics analysis did not reveal any substantial drug-drug interactions. Seven partial responses were observed among the 18 evaluable patients, yielding a treatment response rate of 38.9%.
Conclusions
The combination of
nab
-paclitaxel (100 mg/m
2
) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. This combination therapy also showed promising antitumor activity and was not associated with relevant pharmacokinetic interactions. |
---|---|
ISSN: | 0167-6997 1573-0646 |
DOI: | 10.1007/s10637-011-9674-9 |